Decibel Therapeutics develops treatments to restore and improve hearing, balance

May 31, 2022

A proprietary platform from Decibel Therapeutics is helping to break down the barriers to understanding the molecular pathways and cell physiology inside the inner ear by integrating single-cell genomics, bioinformatic analyses, and precision gene therapy technologies, contends CEO Laurence Reid, PhD.

The biotech company is working on treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine, Reid told ScienceBoard.net at the American Society of Gene & Cell Therapy (ASGCT) 2022 annual meeting in Washington, DC.

"Many people usually think about hearing as a quality-of-life issue and I try to avoid using that phrase, because I think it's really fundamental to cognitive health overall, development early in life, and maintenance of that later in life," Reid said, noting that regenerating hair cells is the "holy grail" for both hearing and balance therapies.

At ASGCT 2022, Decibel Therapeutics presented pre-clinical animal data on its lead investigational gene therapy, DB-OTO, being developed to restore hearing to individuals with a mutation in the otoferlin gene.

Watch the video recording below to learn more.


Mustang Bio focuses on CD20 antigen for CAR T-cell therapy
Biopharmaceutical company Mustang Bio is focused on a CD20-targeted autologous chimeric antigen receptor (CAR) T-cell therapy for non-Hodgkin lymphoma,...
Lexeo to start phase I/II clinical trial for patients with FA cardiomyopathy
Gene therapy company Lexeo Therapeutics in 2022 plans to launch a phase I/II clinical trial of its adeno-associated virus-based therapy designed to intravenously...
Graphite Bio sees its gene editing tech as step above CRISPR
While the use of CRISPR is an effective gene editing tool on its own, Dr. Josh Lehrer, CEO of Graphite Bio, contends that the technology doesn’t correct...
COVID-19 mRNA-based vaccines benefit from decades of research
25 years ago Dr. Drew Weissman, PhD, an infectious disease expert at Penn Medicine, and RNA biologist Kati Kariko, PhD, began their collaboration in...
Genenta Science reports preliminary results of Temferon-glioblastoma study
Biotech company Genenta Science is developing a proprietary hematopoietic stem cell gene therapy, Temferon, for the treatment of a variety of solid tumor...
Next-generation AAV capsids hold key to developing life-changing therapies
Voyager Therapeutics’ discovery platform is identifying novel capsids targeting desired cells and tissues with greater specificity, at lower doses, and...
How to address challenges in producing AAV vectors
There are challenges in producing sufficient quantities of gene therapy products, particularly when it comes to adeno-associated virus (AAV) vectors,...
Atsena Therapeutics’ gene therapy takes aim at childhood blindness
In an interview with ScienceBoard.net, Patrick Ritschel, CEO of Ophthalmology-based gene therapy company Atsena Therapeutics, shared an overview...
Omega Therapeutics looks to tap 'nature's operating system' to control gene expression
Precision genomic medicine company Omega Therapeutics is looking to harness “nature’s operating system” for controlling gene expression and cell differentiation,...
Delivery of gene therapies remains a key challenge
Gene therapy holds great promise for treating inherited disorders, cancers, and other diseases, but delivery of these therapies remains a key challenge,...
Next evolution of CAR T-cell therapy is solid tumors
While chimeric antigen receptor (CAR) T-cell therapy has become a game changer for some patients with blood cancer, the next area of evolution for the...

Copyright © 2022 scienceboard.net

Last Updated 7/20/2022 2:22:32 PM